Group C Type of group

3 trials

Sponsors

SCHERING PLOUGH RESEARCH INSTITUTE,, PRODUCTOS ROCHE Q.F.S.A.,, SEQUELLA INC.,

Unknown Phase

MULTICENTER PROGRAM EXTENDED OPEN MODALITY OF ACCESS WITH ALPHA 2A (RO 25-8310) AS A MONOTERAPY AND COMBINATION THERAPY WITH RIVABIRIN (RO 20-9963) IN PATIENTS WITH CHRONIC HEPATITIS C

Active, not recruitingPER-067-01

PRODUCTOS ROCHE Q.F.S.A.,

Target: 10Updated: 2023-09-04

THERAPEUTIC ALTERNATIVES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

Active, not recruitingPER-003-02

SCHERING PLOUGH RESEARCH INSTITUTE,

Target: 100Updated: 2023-09-04

RANDOMIZED, PLACEBO-CONTROL PHASE III STUDY TO INVESTIGATE THE SECURITY AND EFFECTIVENESS OF THE MPT64 PATCH TEST IN THE DIAGNOSIS OF ACTIVE TUBERCULOSIS (TBC)

Active, not recruitingPER-084-04

Updated: 2023-09-04